The origin of motor fluctuations in Parkinson's disease - Importance of dopaminergic innervation and basal ganglia circuits

被引:136
作者
Obeso, JA
Rodriguez-Oroz, M
Marin, C
Alonso, F
Zamarbide, I
Lanciego, JL
Rodriguez-Diaz, M
机构
[1] Univ Navarra, Clin Univ, FIMA, Dept Neurol & Neurosurg, Pamplona 31180, Spain
[2] Univ Navarra, Clin Univ, FIMA, Dept Histol,Neurosci Ctr, Pamplona, Spain
[3] Univ Navarra, Clin Univ, FIMA, Dept Histol,Neurosci Ctr, E-31080 Pamplona, Spain
[4] Univ Navarra, Sch Med, E-31080 Pamplona, Spain
[5] IDIBAG, Hosp Clin, Fundacio Clin, Expt Neurol Lab, Barcelona, Spain
[6] Univ La Laguna, Sch Med, Dept Physiol, Tenerife, Spain
关键词
D O I
10.1212/WNL.62.1_suppl_1.S17
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The severity of dopamine depletion and the consequent pathophysiologic changes that occur in basal ganglia circuits determine the severity of parkinsonian signs. Restoring the dopamine deficit or the downstream physiologic abnormalities improves Parkinson's Disease (PD) main motor features and as a result, attenuates the short-duration response (SDR). Therefore, both the magnitude and duration of the motor response are a function of the degree of motor severity, which is primarily governed by the loss of tonic dopaminergic activity and disruption of basal ganglia homeostatic mechanisms among which the STN-GPe/GPi circuits play a fundamental role. As neurodegeneration advances, standard levodopa administration give rises to wider oscillations in striatal dopamine availability and "pulsatile" stimulation of striatal dopamine receptors becomes predominant. This induces molecular and physiologic changes that further accentuate and aggravate the SDR that sustains motor fluctuations. Treatments capable of providing and restoring more tonic and physiologic dopaminergic stimulation may avoid many of these abnormalities and lead to better clinical outcomes.
引用
收藏
页码:S17 / S30
页数:14
相关论文
共 90 条
[31]  
Grandas F, 1992, Neurologia, V7, P89
[32]   MOTOR RESPONSE FOLLOWING REPEATED APOMORPHINE ADMINISTRATION IS REDUCED IN PARKINSONS-DISEASE [J].
GRANDAS, F ;
OBESO, JA .
CLINICAL NEUROPHARMACOLOGY, 1989, 12 (01) :14-22
[33]   Risk factors for levodopa-induced dyskinesias in Parkinson's disease [J].
Grandas, F ;
Galiano, ML ;
Tabernero, C .
JOURNAL OF NEUROLOGY, 1999, 246 (12) :1127-1133
[34]  
Grasa JM, 2003, NEUROLOGIA, V18, P29
[35]   Subthalamotomy in Parkinsonian monkeys - Behavioural and biochemical analysis [J].
Guridi, J ;
Herrero, MT ;
Luquin, MR ;
Guillen, J ;
Ruberg, M ;
Laguna, J ;
Vila, M ;
JavoyAgid, F ;
Agid, Y ;
Hirsch, E ;
Obeso, JA .
BRAIN, 1996, 119 :1717-1727
[36]   Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of disinhibition via the globus pallidus [J].
Hassani, OK ;
Mouroux, M ;
Feger, J .
NEUROSCIENCE, 1996, 72 (01) :105-115
[37]   Metabolic effects of nigrostriatal denervation in basal ganglia [J].
Hirsch, EC ;
Périer, C ;
Orieux, G ;
François, C ;
Féger, J ;
Yelnik, J ;
Vila, M ;
Levy, R ;
Tolosa, ES ;
Marin, C ;
Herrero, MT ;
Obeso, JA ;
Agid, Y .
TRENDS IN NEUROSCIENCES, 2000, 23 (10) :S78-S85
[38]  
JENNER P, 2003, NEUROLOGIA S1, V18, P19
[39]   UNEVEN PATTERN OF DOPAMINE LOSS IN THE STRIATUM OF PATIENTS WITH IDIOPATHIC PARKINSONS-DISEASE - PATHOPHYSIOLOGIC AND CLINICAL IMPLICATIONS [J].
KISH, SJ ;
SHANNAK, K ;
HORNYKIEWICZ, O .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (14) :876-880
[40]  
Kumar R, 2000, NEUROLOGY, V55, pS34